Zyversa Therapeutics Stock Performance
| ZVSA Stock | 1.11 0.02 1.77% |
The firm maintains a market beta of -2.1, which attests to a somewhat significant risk relative to the market. As returns on the market increase, returns on owning ZyVersa Therapeutics are expected to decrease by larger amounts. On the other hand, during market turmoil, ZyVersa Therapeutics is expected to outperform it. At this point, ZyVersa Therapeutics has a negative expected return of -1.12%. Please make sure to check out ZyVersa Therapeutics' total risk alpha, as well as the relationship between the skewness and day median price , to decide if ZyVersa Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days ZyVersa Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Last Split Factor 1:10 | Last Split Date 2024-04-26 |
1 | ZyVersa Therapeutics files for mixed shelf offering | 09/03/2024 |
2 | Acquisition by Oconnor Daniel J. of 1750 shares of ZyVersa Therapeutics subject to Rule 16b-3 | 09/25/2024 |
3 | ZyVersa Therapeutics Forms New Scientific Advisory Board to Support Development of Inflammasome ASC Inhibitor IC 100 for Obesity with Metabolic Complications | 10/07/2024 |
4 | ZyVersa Therapeutics Highlights Published Data Demonstrating That Obesity Results in Neuroinflammation Implicated in Development of Neurodegenerative Diseases | 10/22/2024 |
5 | ZyVersa Therapeutics Highlights Published Data Demonstrating the Potential of Inflammasome Inhibition to Protect Pancreatic Islet Beta Cells and Attenuate Progr... | 11/05/2024 |
6 | Anson Funds Management LP Acquires New Stake in ZyVersa Therapeutics Inc | 11/15/2024 |
7 | Disposition of 23404 shares by Oconnor Daniel J. of ZyVersa Therapeutics subject to Rule 16b-3 | 11/22/2024 |
| Begin Period Cash Flow | 5.9 M |
ZyVersa |
ZyVersa Therapeutics Relative Risk vs. Return Landscape
If you would invest 292.00 in ZyVersa Therapeutics on August 27, 2024 and sell it today you would lose (179.00) from holding ZyVersa Therapeutics or give up 61.3% of portfolio value over 90 days. ZyVersa Therapeutics is currently does not generate positive expected returns and assumes 8.2893% risk (volatility on return distribution) over the 90 days horizon. In different words, 73% of stocks are less volatile than ZyVersa, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
ZyVersa Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for ZyVersa Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as ZyVersa Therapeutics, and traders can use it to determine the average amount a ZyVersa Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1347
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ZVSA |
Estimated Market Risk
| 8.29 actual daily | 73 73% of assets are less volatile |
Expected Return
| -1.12 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.13 actual daily | 0 Most of other assets perform better |
Based on monthly moving average ZyVersa Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of ZyVersa Therapeutics by adding ZyVersa Therapeutics to a well-diversified portfolio.
ZyVersa Therapeutics Fundamentals Growth
ZyVersa Stock prices reflect investors' perceptions of the future prospects and financial health of ZyVersa Therapeutics, and ZyVersa Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on ZyVersa Stock performance.
| Return On Equity | -1.52 | ||||
| Return On Asset | -0.25 | ||||
| Current Valuation | (480.08 K) | ||||
| Shares Outstanding | 2.34 M | ||||
| Price To Book | 0.38 X | ||||
| EBITDA | (107.74 M) | ||||
| Net Income | (98.3 M) | ||||
| Total Debt | 8.66 K | ||||
| Book Value Per Share | 27.33 X | ||||
| Cash Flow From Operations | (8.72 M) | ||||
| Earnings Per Share | 491.97 X | ||||
| Market Capitalization | 2.65 M | ||||
| Total Asset | 22.11 M | ||||
| Retained Earnings | (103.22 M) | ||||
| Working Capital | (6.84 M) | ||||
About ZyVersa Therapeutics Performance
By analyzing ZyVersa Therapeutics' fundamental ratios, stakeholders can gain valuable insights into ZyVersa Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if ZyVersa Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if ZyVersa Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (28.36) | (29.78) | |
| Return On Capital Employed | (1.21) | (1.15) | |
| Return On Assets | (4.44) | (4.67) | |
| Return On Equity | (8.88) | (8.43) |
Things to note about ZyVersa Therapeutics performance evaluation
Checking the ongoing alerts about ZyVersa Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for ZyVersa Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| ZyVersa Therapeutics generated a negative expected return over the last 90 days | |
| ZyVersa Therapeutics has high historical volatility and very poor performance | |
| ZyVersa Therapeutics may become a speculative penny stock | |
| ZyVersa Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (98.3 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| ZyVersa Therapeutics generates negative cash flow from operations | |
| ZyVersa Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from gurufocus.com: Anson Funds Management LP Acquires New Stake in ZyVersa Therapeutics Inc |
- Analyzing ZyVersa Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether ZyVersa Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining ZyVersa Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating ZyVersa Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of ZyVersa Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of ZyVersa Therapeutics' stock. These opinions can provide insight into ZyVersa Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for ZyVersa Stock analysis
When running ZyVersa Therapeutics' price analysis, check to measure ZyVersa Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ZyVersa Therapeutics is operating at the current time. Most of ZyVersa Therapeutics' value examination focuses on studying past and present price action to predict the probability of ZyVersa Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ZyVersa Therapeutics' price. Additionally, you may evaluate how the addition of ZyVersa Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Stocks Directory Find actively traded stocks across global markets | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |